Financial terms were not disclosed, although Nordion will leave an estimated US$18m in the company.
Best Medical has acquired all of MDS Nordion, with the exception of the TheraSphere business, which develops liver cancer therapeutics.
The firm bought another Nordion company, Ottawa-based Theratronics, four years ago.
Nordion made a decision in the 2010 financial year to restructure or exit this business, stating that it wanted to reduce complexity, manage costs and focus on growing areas of the business.
The 55 employees at MDS Nordion will transfer to Best Medical, which will also acquire the Belgian production facilities.
Nordion expects the transaction to be completed in the next few months.
Nordion sells Belgian operation
Best Medical to buy MDS Nordion, terms not revealed
You may also like
Analysis
Gas chromatography detectors: A basic introduction
Read moreGas chromatograph (GC) detectors are essential components of GC systems, responsible for monitoring and quantifying the response of compounds as they elute from the GC column after the separation process. Each detector operates on a unique physical or chemical principle and is selected based on the required sensitivity, selectivity, compatibility with the analytes, and the intended application
Trending Articles
You may also like
Analysis
Gas chromatography detectors: A basic introduction
Gas chromatograph (GC) detectors are essential components of GC systems, responsible for monitoring and quantifying the response of compounds as they elute from the GC column after the separation process. Each detector operates on a unique physical or chemical principle and is selected based on the required sensitivity, selectivity, compatibility with the analytes, and the intended application
Manufacturing
Bora Group to acquire MacroGenics’ manufacturing operations and CDMO business
The purchase will hand the Group a biologics drug substance manufacturing facility and a warehousing centre in Maryland, which Bora plans to use in cooperation with Tanvex Biopharma to scale its end-to-end biologics platform
Finance
Cambridge biotech Verinnogen secures £500k CPI investment to advance cancer drug development
The investment will advance a handheld device delivering more precise and reproducible tumour size measurements in preclinical oncology research, addressing variability in existing techniques that can slow drug development and necessitate costly repeat studies
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.